Tart cherry and fish oil for aromatase inhibitor–related joint pain
Official title: An Open Label, Randomized, Waitlist Controlled Trial of Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms
Run by Cedars-Sinai Medical Center · NCT06123286 · Data updated 2026-11-12
This project will test whether taking tart cherry concentrate plus fish oil for 12 weeks reduces joint pain and stiffness in women with breast cancer who are taking aromatase inhibitors.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 30 (estimated) |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Drugs / interventions | prednisone |
| Locations | 2 sites (Los Angeles, California and 1 other locations) |
| Status | Recruiting |
| Started | September 12, 2025 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | August 4, 2026 |
| Trial ID | NCT06123286 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adult women with stage I–III breast cancer on aromatase inhibitors who have BMI ≥27, an Omega-3 index below 8%, and moderate-to-severe joint pain (average BPI ≥4).
✕Probably not a fit
People taking anticoagulant medications, with allergies to cherries or fish, with inflammatory arthritides, uncontrolled diabetes, or a history of stroke/TIA are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This early-phase interventional project gives participants tart cherry concentrate, fish oil, or a combination over a 12-week period to measure changes in joint function and pain. Enrollment targets women with stage I–III breast cancer who are actively receiving aromatase inhibitor therapy and meet specified criteria (including BMI ≥27, Omega-3 index <8%, and average joint pain ≥4). Outcomes will focus on patient-reported joint pain and stiffness, with biochemical and functional measures used as secondary endpoints. The work is conducted at Cedars-Sinai sites in Los Angeles and Torrance, California.
Why it matters
Potential benefit: If successful, the combination could offer a lower-risk, supplement-based option to help reduce AIMSS-related pain and stiffness.
How similar studies have gone: Preclinical mouse studies suggest the two supplements may have additive anti-inflammatory effects, but to our knowledge no prior human trials have tested this specific combination for AIMSS.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Breast cancer diagnosis (Stage I-III) with any hormonal status. * Females aged ≥ 18 years. * Currently receiving AI therapy. * BMI ≥ 27. * Clinical diagnosis of AIMSS. * Omega-3 Index \<8%. * Average joint pain score ≥ 4 on the Brief Pain Inventory (BPI) within 7 days of enrollment. * Written informed consent obtained from subject and ability and willingness of subject to comply with the requirements of the study. Exclusion Criteria: * Current use of anticoagulant medications (Including but not limited to Warfarin, Lovenox, Eliquis, Xarelto). * Allergy to cherries or fish/fish products. * Lifetime history of rheumatoid arthritis and/or inflammatory joint diseases (Including but not limited to reactive arthritis, ankylosing spondylitis, and psoriatic arthritis). * Uncontrolled diabetes mellitus as determined by treating physician (with or without the use of glucose lowering medications and/or insulin). * Lifetime history of stroke or transient ischemic attacks. * New use or dose change of oral or topical analgesics in the previous 14 days. (Including but not limited to opioids, non-steroidal anti-inflammatories, acetaminophen, SNRI's, SSRI's, gabapentinoids, tricyclic antidepressants, and muscle relaxants). * Oral or intra-articular steroid use in the previous 30 days (Including but not limited to dexamethasone, prednisone, methylprednisolone, triamcinolone, hydrocortisone). * History of joint fracture or surgery of the symptomatic joint in the previous 6 months.
Where it's running
-
Cedars-Sinai Medical Center
Los Angeles, California, United States Recruiting -
CS Cancer at the Hunt Cancer Center
Torrance, California, United States Not yet recruiting
Study contacts
- Principal investigator: Philip Chang, DO — Cedars-Sinai Medical Center
- Study coordinator: Clinical Trial Navigator
- Email: GroupCancerTrialInformation@cshs.org
- Phone: 310-423-5842
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Hydroxychloroquine for AIMSS in breast cancer patients on aromatase inhibitors
This study tests whether hydroxychloroquine can reduce joint pain in people with breast cancer who are taking aromatase inhibitors and have AIMSS.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.